Zaleplon is slightly effective in treating insomnia,[7] primarily characterized by difficulty falling asleep. Zaleplon significantly reduces the time required to fall asleep by improving sleep latency and may therefore facilitate sleep induction rather than sleep maintenance.[8][9][10] Due to its ultrashort elimination half-life, zaleplon may not be effective in reducing premature awakenings; however, it may be administered to alleviate
middle-of-the-night awakenings.[8] However, zaleplon has not been empirically shown to increase total sleep time.[10][8]
Zaleplon does not significantly affect driving performance the morning following bedtime administration or 4 hours after middle-of-the-night administration. [11] It may have advantages over
benzodiazepines with fewer adverse effects.[12]
Special populations
Zaleplon is not recommended for chronic use in the elderly.[13] The elderly are more sensitive to the adverse effects of zaleplon such as cognitive side effects. Zaleplon may increase the risk of injury among the elderly. It should not be used during pregnancy or lactation. Clinicians should devote more attention when prescribing for patients with a history of alcohol or drug abuse, psychotic illness, or depression.[14]
In addition, some contend the efficacy and safety of long-term use of these agents remains to be enumerated, but nothing concrete suggests long-term use poses any direct harm to a person.[15]
Adverse effects
The adverse effects of zaleplon are similar to the adverse effects of benzodiazepines, although with less next-day sedation,[16] and in two studies zaleplon use was found not to cause an increase in traffic accidents, as compared to other
hypnotics currently on the market.[17][18]
Sleeping pills, including zaleplon, have been associated with an increased risk of death.[19]
Some evidence suggests zaleplon is not as chemically reinforcing and exhibits far fewer
rebound effects when compared with other nonbenzodiazepines, or
Z-drugs.[20]
Interactions
The
CYP3A4liver enzyme is a minor metabolic pathway for zaleplon, normally metabolizing about 9% of the drug.[5] CYP3A4 inducers such as
rifampicin,
phenytoin,
carbamazepine, and
phenobarbital can reduce the effectiveness of zaleplon, and therefore the FDA suggests that other hypnotic drugs be considered in patients taking a CYP3A4 inducer.[5]
Additional sedation has been observed when zaleplon is combined with
thioridazine, but it is not clear whether this was due to merely an additive effect of taking two sedative drugs at once or a true drug-drug interaction.[21]Diphenhydramine, a weak inhibitor of aldehyde oxidase, has not been found to affect the pharmacokinetics of zaleplon.[21]
Pharmacology
Mechanism of action
Zaleplon is a high-selectivity,[22] high-affinity ligand of positive modulator sites of GABAA receptors, which enhances GABAergic inhibition of neurotransmission in the central nervous system. The ultrashort
half-life gives zaleplon a unique advantage over other hypnotics because of its lack of next-day residual effects on driving and other performance-related skills.[23][24] Unlike nonselective benzodiazepine drugs and zopiclone, which distort the
sleep pattern, zaleplon appears to induce sleep without disrupting the normal
sleep architecture.[25]
A
meta-analysis of randomized, controlled
clinical trials which compared benzodiazepines against zaleplon or other Z-drugs such as zolpidem, zopiclone, and eszopiclone has found few clear and consistent differences between zaleplon and the benzodiazepines in terms of
sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events,
tolerance,
rebound insomnia, and daytime
alertness.[26]
Zaleplon should be understood as an ultrashort-acting sedative-hypnotic drug for the treatment of insomnia. Zaleplon increases
EEG power density in the δ-frequency band and a decrease in the energy of the θ-frequency band[27][28]
Pharmacokinetics
Zaleplon is primarily metabolised by
aldehyde oxidase into 5-oxozaleplon, and its half-life may be affected by substances which inhibit or induce aldehyde oxidase. According to urine analysis, about 9% of zaleplon is metabolized by
CYP3A4 to form desethylzaleplon, which is quickly metabolized by aldehyde oxidase to 5-oxodesethylzaleplon.[5][4] All of these metabolites are inactive.[4] When taken orally, zaleplon reaches maximum concentration in about 45 minutes.[4]
The synthesis starts with the condensation of
3-acetylacetanilide[32][33] (1) with N,N-dimethylformamide dimethyl acetal (
DMFDMA)[34] to give the eneamide (2). The anilide nitrogen is then alkylated by means of
sodium hydride and
ethyl iodide to give 3. The first step in the condensation with 3-amino-4-cyanopyrazole can be visualized as involving an
addition-elimination reaction sequence on the eneamide function to give a transient intermediate such as 5. Cyclization then leads to formation of the fused
pyrimidine ring to afford zaleplon (6).
Society and culture
Recreational use
Zaleplon has the potential to be a drug of recreational use, and has been found to have an addictive potential similar to benzodiazepine and benzodiazepine-like hypnotics.[35]
Some individuals use a different delivery method than prescribed, such as
insufflation, to induce effects faster.[36]
Sonata 10-mg capsules
Anterograde amnesia can occur and can cause one to lose track of the amount of zaleplon already ingested, prompting the ingesting of more than originally planned.[37][38]
Aviation use
The
Federal Aviation Administration allows zaleplon with a 12-hour wait period and no more than twice a week, which makes it the sleep medication with the shortest allowed waiting period after use.[39] The substances with the 2nd shortest period, which is of 24 hours, are zolpidem and
ramelteon.[39]
Military use
The
United States Air Force uses zaleplon as one of the hypnotics approved as a "
no-go pill" to help aviators and special-duty personnel sleep in support of mission readiness (with a four-hour restriction on subsequent flight operation). "Ground tests" are required prior to authorization being issued to use the medication in an operational situation.[40] The other hypnotics used as "no-go pills" are
temazepam and
zolpidem, which both have longer mandatory recovery periods.[40]
^Elie R, Rüther E, Farr I, Emilien G, Salinas E (August 1999). "Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group". The Journal of Clinical Psychiatry. 60 (8): 536–44.
doi:
10.4088/JCP.v60n0806.
PMID10485636.
^Bain KT (June 2006). "Management of chronic insomnia in elderly persons". The American Journal of Geriatric Pharmacotherapy. 4 (2): 168–92.
doi:
10.1016/j.amjopharm.2006.06.006.
PMID16860264.
^Wagner J, Wagner ML, Hening WA (June 1998). "Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia". The Annals of Pharmacotherapy. 32 (6): 680–91.
doi:
10.1345/aph.17111.
PMID9640488.
S2CID34250754.
^Menzin J, Lang KM, Levy P, Levy E (January 2001). "A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France". PharmacoEconomics. 19 (1): 69–78.
doi:
10.2165/00019053-200119010-00005.
PMID11252547.
S2CID45013069.
^Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A (March 2002). "Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol". Sleep. 25 (2): 224–31.
PMID11905433.
^Lader MH (January 2001). "Implications of hypnotic flexibility on patterns of clinical use". International Journal of Clinical Practice. Supplement (116): 14–9.
PMID11219327.
^Binding assays show no binding (IsC50 > 10,000 micromolar) with regards to the 5HT1, 5HT1A, 5-HT2A, 5-HT3, D1, D2, alpha-1 adrenoceptor, alpha-2 adrenoceptor, or M1 receptors. Noguchi H, Kitazumi K, Mori M, Shiba T (January 2002). "Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic". European Journal of Pharmacology. 434 (1–2): 21–28.
doi:
10.1016/S0014-2999(01)01502-3.
PMID11755161.
^Patat A, Paty I, Hindmarch I (July 2001). "Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent". Human Psychopharmacology. 16 (5): 369–392.
doi:
10.1002/hup.310.
PMID12404558.
S2CID21096374.
^Rowlett JK, Spealman RD, Lelas S, Cook JM, Yin W (January 2003). "Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABA(A)/alpha1 receptors". Psychopharmacology. 165 (3): 209–215.
doi:
10.1007/s00213-002-1275-z.
PMID12420154.
S2CID37632215.
^Noguchi H, Kitazumi K, Mori M, Shiba T (January 2002). "Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic". European Journal of Pharmacology. 434 (1–2): 21–28.
doi:
10.1016/S0014-2999(01)01502-3.
PMID11755161.
^Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (July 2004). "Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis". Human Psychopharmacology. 19 (5): 305–22.
doi:
10.1002/hup.594.
PMID15252823.
S2CID10888200.
^Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, et al. (April 2006). "Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors". The Journal of Pharmacology and Experimental Therapeutics. 317 (1): 369–77.
doi:
10.1124/jpet.105.096701.
PMID16399882.
S2CID46510829.
^"Zaleplon". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 10 June 2018.
^Dehmel F, Weinbrenner S, Julius H, Ciossek T, Maier T, Stengel T, et al. (July 2008). "Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles". Journal of Medicinal Chemistry. 51 (13): 3985–4001.
doi:
10.1021/jm800093c.
PMID18558669.
^Salomon RG, Raychaudhuri SR (1984). "Convenient preparation of N,N-dimethylacetamide dimethyl acetal". The Journal of Organic Chemistry. 49 (19): 3659–3660.
doi:
10.1021/jo00193a045.
^Rush CR, Frey JM, Griffiths RR (July 1999). "Zaleplon and triazolam in humans: acute behavioral effects and abuse potential". Psychopharmacology. 145 (1): 39–51.
doi:
10.1007/s002130051030.
PMID10445371.
S2CID12061258.
^Ator NA (December 2000). "Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons". Drug and Alcohol Dependence. 61 (1): 55–68.
doi:
10.1016/S0376-8716(00)00123-X.
PMID11064184.